Key statistics
As of last trade Amneal Pharmaceuticals Inc (2DT:FRA) traded at 7.70, -9.94% below its 52-week high of 8.55, set on Nov 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.95 |
---|---|
High | 8.00 |
Low | 7.70 |
Bid | 7.80 |
Offer | 8.15 |
Previous close | 7.60 |
Average volume | 744.67 |
---|---|
Shares outstanding | 309.54m |
Free float | 131.79m |
P/E (TTM) | -- |
Market cap | 2.58bn USD |
EPS (TTM) | -0.6835 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 14:29 GMT.
More ▼
Press releases
- Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
- Amneal Reports Third Quarter 2024 Financial Results
- Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
- Amneal to Report Third Quarter 2024 Results on November 8, 2024
- Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
- Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
- Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
More ▼